cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.25402/fon.23997990.v1
title: Association between event-free survival and overall survival in early-stage triple-negative breast cancer - supplementary material

description: <b>Table S1</b>. Key characteristics of single-arm trials and cohort studies<b>Table S2</b>. Base case and sensitivity analyses of individual-level association<b>Table S3.</b> Predicted results for the trials with immunotherapy using the model without fixed intercept based on non-immunotherapy trials<b>Table S4.</b> Validation of individual level association<b>Table S5.</b> Search strategy for the target literature review<b>Figure S1.</b> PRISMA chart<b>Figure S2.</b> Trial-level association between EFS and OS excluding immunotherapy trials<b>Figure S3.</b> Validation of trial-level association
DOI: 10.25402/fon.24015012
title: Achieving white blood cell equity: Are the safety profiles of biosimilar and reference pegfilgrastims comparable? - Supplementary material

description: Supplementary Table 1. Included studies.Supplementary Table 2. Subject demographics for phase I clinical trials.Supplementary Table 3. Patient demographics for phase III clinical trials.Supplementary Table 4.<b> </b>Summary of safety results of phase I studies of biosimilar pegfilgrastims in healthy subjectsSupplementary Table 5. Summary of the most common (&gt;5% of subjects) TEAEs in phase I studies of biosimilar pegfilgrastims in healthy subjectsSupplementary Table 6. Summary of the most common (&gt;5% of subjects) TEAEs in phase III studies of biosimilar pegfilgrastims in patients with breast cancer receiving myelosuppressive chemotherapy
DOI: 10.25402/fon.24015012.v1
title: Achieving white blood cell equity: Are the safety profiles of biosimilar and reference pegfilgrastims comparable? - Supplementary material

description: Supplementary Table 1. Included studies.Supplementary Table 2. Subject demographics for phase I clinical trials.Supplementary Table 3. Patient demographics for phase III clinical trials.Supplementary Table 4.<b> </b>Summary of safety results of phase I studies of biosimilar pegfilgrastims in healthy subjectsSupplementary Table 5. Summary of the most common (&gt;5% of subjects) TEAEs in phase I studies of biosimilar pegfilgrastims in healthy subjectsSupplementary Table 6. Summary of the most common (&gt;5% of subjects) TEAEs in phase III studies of biosimilar pegfilgrastims in patients with breast cancer receiving myelosuppressive chemotherapy
DOI: 10.25549/examiner-c44-52233
title: Chavez Ravine (City Council), 1959

description: 10 images. Chavez Ravine (City Council), 15 May 1959. L.E. Timberlake; Karl L. Rundberg; Harry Watson; Mrs. Alice Martin; Ed Clarke; Clete Roberts; Paul Weeks.; Caption slip reads: "Photographer: Wilson. Date: 1959-05-15. Assignment: Chavez Ravine -- City Council. 140: Paul Weeks, newsman, sworn in (Mirror News), tells of Mrs. Martin's statements. 139, L - R: Mrs. Alice Martin and Paul Weeks; she denies his articles on acting. 60-61, 57-58: Cameraman Harry Watson, K.T.T.V. shoots Mrs. Alice Martin at microphone, presumably invited here by George Putnam, news forecaster. 32: At mike, Ed Clarke of TV News; Clete Roberts on his left; and cameraman Clarke tells how he asked Mrs. Martin to sit in her rocking chair and be carried out. 67: Rundberg reads. 36: Karl Rundberg. 35: L.E. Timberlake. 110: Rundberg holds up newspaper saying Mrs. Martin was acting for TV (Mirror News). 109: L - R: Rundberg and Timberlake. 98-99: Mrs. Alice Martin, who claims she did no acting for TV".
DOI: 10.25402/fon.24081594
title: REAL-WORLD RELATIONSHIP OF EARLY ENDPOINTS TO SURVIVAL ENDPOINTS IN PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER - supplementary material

description: Supplementary Table 1: Landmark analysisSupplementary Figure 1: Correlation between event-free survival and overall surviva
DOI: 10.25402/fon.24081594.v1
title: REAL-WORLD RELATIONSHIP OF EARLY ENDPOINTS TO SURVIVAL ENDPOINTS IN PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER - supplementary material

description: Supplementary Table 1: Landmark analysisSupplementary Figure 1: Correlation between event-free survival and overall surviva
DOI: 10.25402/fon.24105477
title: Real-world outcomes for first line next-generation hormonal agents in metastatic prostate cancer: a systematic review - Supplementary material

description: Supplementary Appendix Supplementary Figures 1-4 Supplementary Tables 1-25
DOI: 10.25402/fon.24105477.v1
title: Real-world outcomes for first line next-generation hormonal agents in metastatic prostate cancer: a systematic review - Supplementary material

description: Supplementary Appendix Supplementary Figures 1-4 Supplementary Tables 1-25
DOI: 10.25549/examiner-c44-48757
title: Sports Arena, 1959

description: 4 images. Sports Arena, 25 February 1959. Negative of the exterior; Negative of general exteriors showing progress.; Caption slip reads: "Photographer: Snow. Date: 02-25. Assignment: Sports Arena. Special Instructions: negs to Baker. 39-40: 2 plate pan of exterior. 91-92: General exteriors showing progress".
DOI: 10.25402/fon.24182565
title: CSF-Administered Therapies for Leptomeningeal Metastases from Solid Tumors - supplementary material

description: Supplementary File A: Table Compiling Key Data from Intrathecal trials for treatment of Leptomeningeal Metastasis (LM)
DOI: 10.25549/examiner-c44-51933
title: Dodgers boosters for Prop-B (on TV), 1958

description: 25 images. Dodgers boosters for Prop-B (on TV), 1 June 1958. Babe Dahlgren; Bill Beechler -- 12 years; Consuelo De Bonzo; Mervyn Leroy; Jack Benny; Rosalind Wyman; George Burns; Pat Mowry (Miss New Hampshire); Adelina Pedroza -- 8 years; Clive Hermann; Henry Armstrong; Ted Husing; Corrine Griffith; Danny Goodman; Dean Martin; Walter O'Malley; Jeff Chandler; Danny Thomas; Bill Frawley; George Gose; H.C. McClellan; Gloria Wood; Bobby Merwin -- 8 years; Ray Bolger; Vic Bailey -- 13 years; Alan Horrocks -- 13 years; Gordon Blonsky -- 11 years; Charles W. Ross; Chester Quon; Henry Lowe; Joe E. Brown; Jerry Lewis.; Caption slip reads: "Photographer: Rustan. Date: 1958-06-01. Reporter: Cowles. Assignment: Dodgers. 11-12, Left to right: Bobby Merwin, 8; Vic Bailey, 13; Alan Horrocks, 13; Gordon Blonsky, 11; Charles W. Ross, second vice president of Dodgers Fan Club, all join in cheers for Los Angeles Dodgers and boost for Prop. B at TV telethon. Boys are members of Little League and Babe Ruth League. 29-30: Chester Quon, president, Chinese Chamber of Commerce; Henry Lowe, president, Chinese Armenian Citizens Alliance".; Other caption slip reads: "Photograper: Gray & Olmo. Date: 06-02. Reporter: Brown. Dodgers TV. G25-26, L to R: Ted Husing, former sports announcer; Corrine Griffith, old-time actress. G3-1, L to R: Babe Dahlgren, old-time ball player; Bill Beechler, 12, of Kiwanis Club; Consuelo De Bonzo. O11-12: Mervyn Le Roy; Jack Benny; Rosalind Wyman; George Burns; Pat Mowry 'Miss New Hampshire'. G87-88, L to R: Danny Goodman; Dean Martin; Walter O'Malley; Jeff Chandler. O9-10, L to R: Jeff Chandler; Danny Thomas; Walter O'Malley; Bill Frawley with Dodger rooter caps. 29-30, L to R: Gloria Wood; Ray Bolger; autograph arm cast of Bobby Mervin, 8, of Moorpark Athletics of National Little League. 105-106: Mrs. Elsa Watson, 22; daughter Cynthia, 8 months; boy, James Stoner, 11; Mrs. Ron Gayton, 22; Genelle, daughter, 2 1/2 with sign, 'Buenvenados Dodgers' (welcome). R6-7-8: Adelina Pedroza, 8, Spanish dancer; Clive Herman and Henry Armstrong in background. 99-100: Dodgers & Red Sox teams of Westchester National Little League. 33-34, 103-104: Long shot and close ups (natural lite) of Joe E. Brown and Mervyn Le Roy. R1-2-3, L to R: George Gose, Chamber of Commerce President, H.C. McClellan, who drew up contract for Dodgers; Chart of Acreage, Chavez Ravine. 29, Left to Right: Gloria Wood, singer; Bobby Merwin, 8, Moorpark Athletics Little League Babe team. Roy Bolger, authograph cast".
DOI: 10.25402/fon.24182565.v1
title: CSF-Administered Therapies for Leptomeningeal Metastases from Solid Tumors - supplementary material

description: Supplementary File A: Table Compiling Key Data from Intrathecal trials for treatment of Leptomeningeal Metastasis (LM)
DOI: 10.25402/fon.24204036
title: Treatment-Related Gastrointestinal Adverse Events of Nivolumab plus Ipilimumab: A Systematic Review and Meta-analysis - supplementary material

description: PRISMA 2020 Checklist
DOI: 10.25402/fon.24204036.v1
title: Treatment-Related Gastrointestinal Adverse Events of Nivolumab plus Ipilimumab: A Systematic Review and Meta-analysis - supplementary material

description: PRISMA 2020 Checklist
DOI: 10.25402/fon.24230068
title: microRNA-767 and its binding site polymorphism in mTOR gene act as potential biomarkers for female reproductive cancers - supplementary material

description: <b>Supplementary Table 1:</b><b> </b>Demographic and histopathological parameters of cases and controls.<b>Supplementary Table 2: </b>Primers for microRNA-767, U6 and Tetra-ARMS PCR primers for mTOR(rs2536) SNP<b>Supplementary </b><b>Table 3: </b>PCR conditions for tetra arms PCR<b>Supplementary</b><b> Table 4: </b>PCR conditions of qPCR for microRNA-767 and U6
DOI: 10.25549/examiner-c44-52484
title: Baseball, Dodgers arrival, 1959

description: 5 images. Baseball, Dodgers arrival, 28 September 1959. Mr. and Mrs. Don Demeter (Betty) and baby; Mr. and Mrs. Larry Sherry (Sally); Mr. and Mrs. Walter O'Malley; Fred Haney (Brave's arrival); Ed Matthews (Brave's arrival). (Sleeve reads: SP-12662).; Caption slip reads: "Photographer: Wesselmann. Date: 1959-09-28. Assignment: Dodgers arrival. 15/58/57/16: Crowd shots. 61: Manager Fred Haney, left; Ed Matthews. 62: Coming of Braves plane. 4. Dodgers debark from plane. 3. Don Demeter, wife Betty, son Russ, six months. 54: Wives waving to husbands. 1: Larry Sherry and wife, Sally. 2: Mr. and Mrs. Walter O'Malley; Larry Sherry and wife, Sally".
DOI: 10.25402/fon.24230068.v1
title: microRNA-767 and its binding site polymorphism in mTOR gene act as potential biomarkers for female reproductive cancers - supplementary material

description: <b>Supplementary Table 1:</b><b> </b>Demographic and histopathological parameters of cases and controls.<b>Supplementary Table 2: </b>Primers for microRNA-767, U6 and Tetra-ARMS PCR primers for mTOR(rs2536) SNP<b>Supplementary </b><b>Table 3: </b>PCR conditions for tetra arms PCR<b>Supplementary</b><b> Table 4: </b>PCR conditions of qPCR for microRNA-767 and U6
DOI: 10.25402/fon.24241636
title: As a potential predictor of pan-cancer, UBE2S is related to tumor-associated macrophage infiltration - supplementary material

description: Supplementary Figures 1-4Table S1. TCGA database and GTEx database sample summaryTable S2. Immune score of UBE2S in pan-cancerTable S3 Functional enrichment analysis of UBE2S in pan-cancerTable S4 Enrichment analysis of signal pathway of UBE2S in pan-cancer
DOI: 10.25402/fon.24241636.v1
title: As a potential predictor of pan-cancer, UBE2S is related to tumor-associated macrophage infiltration - supplementary material

description: Supplementary Figures 1-4Table S1. TCGA database and GTEx database sample summaryTable S2. Immune score of UBE2S in pan-cancerTable S3 Functional enrichment analysis of UBE2S in pan-cancerTable S4 Enrichment analysis of signal pathway of UBE2S in pan-cancer
DOI: 10.25402/fon.24258787
title: Prognostic significance of the SIRI in gastrointestinal malignancy patients: a pooled analysis of 10091 participants - supplementary material

description: PRISMA 2020 ChecklistTable S1. Quality assessment of included studies.Table S2. Meta-regression analyses for the association of confounding factors and the hazard ratio for OS and DFS.Figure S1. The flowchart of study selection.Figure S2. Sensitivity analyses for OS (A) and DFS (B) between the high SIRI and low SIRI groups in GI malignanciesFigure S3. Begg’s funnel plots for OS (A) and DFS (B) between the high SIRI and low SIRI groups in GI malignancies.
DOI: 10.25402/fon.24258787.v1
title: Prognostic significance of the SIRI in gastrointestinal malignancy patients: a pooled analysis of 10091 participants - supplementary material

description: PRISMA 2020 ChecklistTable S1. Quality assessment of included studies.Table S2. Meta-regression analyses for the association of confounding factors and the hazard ratio for OS and DFS.Figure S1. The flowchart of study selection.Figure S2. Sensitivity analyses for OS (A) and DFS (B) between the high SIRI and low SIRI groups in GI malignanciesFigure S3. Begg’s funnel plots for OS (A) and DFS (B) between the high SIRI and low SIRI groups in GI malignancies.
DOI: 10.25402/fon.24270739
title: Genetic markers of Chronic Lymphocytic Leukemia: A retrospective study of 312 patients from a reference center in Lebanon - supplementary material

description: <b>Supplementary Table 1.</b> Chromosomal abnormalities detected by patient karyotype analysis<b>Supplementary Table 2.</b> Associations between the <i>IGHV</i> mutational status and the other genetic markers<b>Supplementary Table 3.</b> Associations between karyotype complexity and the genetic alterations detected by FISH
DOI: 10.25549/examiner-c44-52322
title: Baseball writers, Dodgers dinner, 1959

description: 12 images. Baseball writers, Dodgers dinner, 13 April 1959. Carl Furillo; John Roseboro; Stan Musial; Rosalind Wyman; Pee Wee Reese; Art Linkletter; Duke Snider; Roy Campanella; Stan Williams; Dinah Shore; Frank Sinatra. (Sleeve reads: SP-12568).; Caption slip reads: "Photographer: Wesselmann. Date: 1959-04-13. Assignment: Dodgers dinner at Beverly Hilton. 9-10: Dinah Shore sings. 15-16: Frankie Sinatra sings".; Other caption slip reads: "Photographer: Lou Mack. Date: 1959-04-13. Assignment: Campanella dinner. 29-30, L to R: Stan Musial; Roy Campanella and Pee Wee Reese. 9-10, L to R: John Roseboro; Stan Musial; Rosalind Wyman who received civic award; Stan William; Pee Wee Reese and Carl Furillo. 40-41: Carl Furillo; John Roseboro; Stan Musial; Rosalind Wyman; Stan Williams; Pee Wee Reese and Art Linkletter. 17-18: Duke Snider hands Campanella avocadoes".
DOI: 10.25402/fon.24270739.v1
title: Genetic markers of Chronic Lymphocytic Leukemia: A retrospective study of 312 patients from a reference center in Lebanon - supplementary material

description: <b>Supplementary Table 1.</b> Chromosomal abnormalities detected by patient karyotype analysis<b>Supplementary Table 2.</b> Associations between the <i>IGHV</i> mutational status and the other genetic markers<b>Supplementary Table 3.</b> Associations between karyotype complexity and the genetic alterations detected by FISH
DOI: 10.25402/fon.24270778
title: In class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma - Supplementary Material

description: Supplementary Figure S1. Study design and timelinesSupplementary Figure S2. Populations for the IRd and V-based cohorts Selected from US MM-6 and INSIGHT MM.Supplementary Table S1. Patient baseline and disease characteristics before IPTW.Supplementary Table S2. Duration of treatment with individual agents in the IRd and V-based IPTW-weighted cohorts.Supplementary Table S3. Stem cell transplant and subsequent PI therapy in the V-based IPTW-weighted cohort.<br>
DOI: 10.25402/fon.24270778.v1
title: In class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma - Supplementary Material

description: Supplementary Figure S1. Study design and timelinesSupplementary Figure S2. Populations for the IRd and V-based cohorts Selected from US MM-6 and INSIGHT MM.Supplementary Table S1. Patient baseline and disease characteristics before IPTW.Supplementary Table S2. Duration of treatment with individual agents in the IRd and V-based IPTW-weighted cohorts.Supplementary Table S3. Stem cell transplant and subsequent PI therapy in the V-based IPTW-weighted cohort.<br>
DOI: 10.25402/fon.24278275
title: Capecitabine Maintenance Therapy in Metastatic Colorectal Cancer Patients with No Evidence of Disease - supplementary material

description: CONSORT 2010 checklist of information to include when reporting a randomised trialTable S1. Cox analysis for disease-free survival and overall survival by baseline factors
DOI: 10.25402/fon.24278275.v1
title: Capecitabine Maintenance Therapy in Metastatic Colorectal Cancer Patients with No Evidence of Disease - supplementary material

description: CONSORT 2010 checklist of information to include when reporting a randomised trialTable S1. Cox analysis for disease-free survival and overall survival by baseline factors
DOI: 10.25402/fon.24278305
title: Real-world treatment patterns, healthcare resource utilization, and costs among patients with peripheral T-cell lymphoma - supplementary material

description: <b>Supplemental Table 1. Baseline demographic and clinical characteristics of the overall, untreated and steroid-only cohorts.</b>
DOI: 10.25549/examiner-c44-51812
title: Dodgers welcome and parade, 1958

description: 41 images. Dodgers welcome and parade, 18 April 1958. Charles Dressen; Walter Alston; Mayor and Mrs. George Christopher; George Hearst; Walter O'Malley; Mayor Norris Poulson; Norris Brandt (Poulson's grandson); F.M. Parker; Danny Parker -- 3 1/2 years; Bobby Parker -- 4 1/2 years. (Negatives by Paegel, Olmo, Snow, Mitchell).; Caption slip reads: "Photographer: Mitchell. Date: 1958-04-18. Reporter: Bernstein. Assignment: Baseball at City Hall. 7: Charles Dressen; Walter Alston. 8: Parade looking north from First Street and Beaudry. 47: Mayor George Christopher and his wife from San Francisco. 48. Mayor George Christopher; Mrs. Christopher; George Hearst. 9: Walter O'Malley wears Serape and sombrero, gift of Olvera Street. 10: Walter O'Malley with (monkey) Gino. 57: Mayor Norris Poulson; Walter O'Malley; Home plate. 58: L to R: Mayor Norris Poulson; grandson Norris Brandt; Mrs. Poulson. 59: Walter O'Malley; Foghorn Murphy on horse patches. 60: Mayor Norris Poulson".; Other caption slip reads: "Photographer: Paegel. Date: 1958-04-18. Reporter: Thackrey. Assignment: Crowd sidebar. F.M. Parker of Alhambra and his grandsons, Danny, 3 1/2, who caught a ball, and Bobby, 4 1/2, who didn't".
DOI: 10.25402/fon.24278305.v1
title: Real-world treatment patterns, healthcare resource utilization, and costs among patients with peripheral T-cell lymphoma - supplementary material

description: <b>Supplemental Table 1. Baseline demographic and clinical characteristics of the overall, untreated and steroid-only cohorts.</b>
DOI: 10.25402/fon.24297763
title: siRNA-Based Approach for Castration-Resistant Prostate Cancer Therapy Targeting Androgen Receptor Signaling Pathway - Supplementary material

description: <b>Supplementary Table 1. </b>The major characteristics of CSPC and CRPC. CSPC, Castration-Sensitive Prostate Cancer; CRPC, Castration-Resistant Prostate Cancer.<b>Supplementary</b><b> T</b><b>able 2</b>. Interventional clinical trials of siRNA use for cancer. Search criteria: Cancer, siRNA. (Accessed in December 2022, sorted from the newest to the oldest start dates). U.S., United States; U.K., United Kingdom.<br>
DOI: 10.25402/fon.24297763.v1
title: siRNA-Based Approach for Castration-Resistant Prostate Cancer Therapy Targeting Androgen Receptor Signaling Pathway - Supplementary material

description: <b>Supplementary Table 1. </b>The major characteristics of CSPC and CRPC. CSPC, Castration-Sensitive Prostate Cancer; CRPC, Castration-Resistant Prostate Cancer.<b>Supplementary</b><b> T</b><b>able 2</b>. Interventional clinical trials of siRNA use for cancer. Search criteria: Cancer, siRNA. (Accessed in December 2022, sorted from the newest to the oldest start dates). U.S., United States; U.K., United Kingdom.<br>
DOI: 10.25402/fon.24304642
title: Real-world evidence on multiple myeloma treated in 2013-2019 in the Hospital District of Helsinki and Uusimaa, Finland - Supplementary material

description: Supplementary figure 1. The annual incidence of stem cell transplantation (SCT) eligible multiple myeloma patients with 95% confidence intervals in 2013–2018 estimated as the number of SCT procedures (only the first SCT procedure per patient considered) among initiated first-line immunochemotherapies in each year. Both incidence per each year (solid line) and mean incidence (dashed line; Mann Kendall trend test p-value, 0.71) are provided.Supplementary figure 2. All-cause health care resource use per patient year (PPY; with 95% confidence intervals) in multiple myeloma patients with and without record(s) on stem cell transplantation (SCT). Patients diagnosed and treated in the Hospital District of Helsinki and Uusimaa, Finland, in 2013–2019 were included.Supplementary figure 3. Cox proportional multivariable hazards models assessing the effect of the patient characteristics (age, sex, and Charlson Comorbidity Index, CCI) at diagnosis and diagnosis year on the overall survival.Supplementary table 1. Multiple myeloma medications and respective codes utilized in the studySupplementary table 2. ICD-10 diagnoses recorded five years prior to the first ICD-10 record on multiple myeloma as a diagnosis, among 509 adult patients diagnosed and treated with immunochemotherapy in 2013–2019 in the Hospital District of Helsinki and Uusimaa, Finland.Supplementary table 3. The number of multiple myeloma patients with each type of induction/reinduction treatment in the first three lines of immunochemotherapy (ICT; for the abbreviations, see the Supplementary table 1). ICTs started in 2013–2016 (“Pre 2017”) and 2017–2019 (“Post 2017”) are separately reportedSupplementary methods
DOI: 10.25402/fon.24304642.v1
title: Real-world evidence on multiple myeloma treated in 2013-2019 in the Hospital District of Helsinki and Uusimaa, Finland - Supplementary material

description: Supplementary figure 1. The annual incidence of stem cell transplantation (SCT) eligible multiple myeloma patients with 95% confidence intervals in 2013–2018 estimated as the number of SCT procedures (only the first SCT procedure per patient considered) among initiated first-line immunochemotherapies in each year. Both incidence per each year (solid line) and mean incidence (dashed line; Mann Kendall trend test p-value, 0.71) are provided.Supplementary figure 2. All-cause health care resource use per patient year (PPY; with 95% confidence intervals) in multiple myeloma patients with and without record(s) on stem cell transplantation (SCT). Patients diagnosed and treated in the Hospital District of Helsinki and Uusimaa, Finland, in 2013–2019 were included.Supplementary figure 3. Cox proportional multivariable hazards models assessing the effect of the patient characteristics (age, sex, and Charlson Comorbidity Index, CCI) at diagnosis and diagnosis year on the overall survival.Supplementary table 1. Multiple myeloma medications and respective codes utilized in the studySupplementary table 2. ICD-10 diagnoses recorded five years prior to the first ICD-10 record on multiple myeloma as a diagnosis, among 509 adult patients diagnosed and treated with immunochemotherapy in 2013–2019 in the Hospital District of Helsinki and Uusimaa, Finland.Supplementary table 3. The number of multiple myeloma patients with each type of induction/reinduction treatment in the first three lines of immunochemotherapy (ICT; for the abbreviations, see the Supplementary table 1). ICTs started in 2013–2016 (“Pre 2017”) and 2017–2019 (“Post 2017”) are separately reportedSupplementary methods
DOI: 10.25402/fon.24336334
title: Cetuximab every-2-weeks versus standard weekly dosing administration schedule - supplementary material

description: <b>Table S1. </b>Studies evaluating cetuximab Q2W plus irinotecan in <i>KRAS</i>-unselected patients<b>Table S2. </b>Studies evaluating cetuximab Q2W plus irinotecan in patients with (<i>K)RAS</i> wt mCRC<b>Table S3. </b>Studies evaluating cetuximab Q2W plus triplet CT in patients with <i>KRAS</i> wt mCRC<b>Table S4. </b>Studies evaluating cetuximab Q2W and Q1W plus intermittent Nordic FLOX* in patients with <i>KRAS</i> exon 2 wt mCRC<b>Table S5. </b>Comparable safety with Q1W and Q2W dosing<b>Table S6. </b>Grade 3/4 AEs in special categories*<b>Table S7. </b>Studies evaluating cetuximab Q2W as first line for R/M SCCHN<br>